Sustainability and Corporate Social Responsibility at CSL

CSL is committed to a healthier world. Our vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture.

For over a century we have earned trust by striving to fulfill our promise to improve the lives of our patients and donors and safeguard public health. We remain committed to providing innovative medicines with an unparalleled level of care to drive a sustainable future for generations to come.

The sustainable growth of our business relies upon us staying true to our purpose, driving responsible and ethical behaviours with integrity and further embedding sustainability considerations and practices across our organisation. While it won't be without challenges, we are committed to this path.

Environmental Sustainability

Our commitment to a healthier world means delivering for both people and our planet. We take this responsibility seriously, and our promise is to continue to further build environmental considerations into our business so we can deliver a sustainable world for the next century and beyond. CSL views environmental stewardship as its responsibility and an opportunity to build healthier and more sustainable communities.

CSL recognises that responsible management and efficient use of natural resources is key to the company’s sustainable growth and its ability to deliver an efficient and reliable supply of life-saving medicines. We support meeting the goals of the Paris Agreement to avoid the worst impacts of climate change as identified by the Intergovernmental Panel on Climate Change (IPCC).

Community Impact and Philanthropy

SL is committed to advancing equitable access to its medicines and vaccines by designing access and affordability programs to serve vulnerable populations and expand strategic donations.


Through extension of CSL's existing World Federation of Haemophilia (WFH) partnership, by FY2030, CSL aims to donate products that enable 2,100 people with bleeding disorders to access prophylaxis therapy across 25 low- and middle-income countries. In support of reaching more communities and patients, through discounted products, CSL has announced a new aspirational commitment to treat up to 450,000 people with anaemia in at least three low- and middle-income countries with CSL Vifor's Ferinject® by FY2030